Comparative Pharmacology
Head-to-head clinical analysis: ERGOLOID MESYLATES versus HYDROGENATED ERGOT ALKALOIDS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ERGOLOID MESYLATES versus HYDROGENATED ERGOT ALKALOIDS.
ERGOLOID MESYLATES vs HYDROGENATED ERGOT ALKALOIDS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ergoloid mesylates is a mixture of ergot alkaloids that acts as a partial agonist at dopamine D2 receptors and antagonist at alpha-adrenergic receptors, improving cerebral metabolism and blood flow.
Hydrogenated ergot alkaloids act as partial agonists/antagonists at α-adrenergic receptors, serotonergic (5-HT1B/1D) receptors, and dopaminergic receptors. They cause vasoconstriction by activating α-adrenoceptors and 5-HT receptors on vascular smooth muscle, and inhibit prolactin secretion via D2 receptor agonism.
Oral: 1 mg three times daily. Titrate to 2 mg three times daily after 2 weeks if tolerated.
1 mg orally three times daily, or 0.3 mg intramuscularly or subcutaneously once daily.
None Documented
None Documented
2-4 hours for parent drug; clinical significance: drug accumulation unlikely with normal dosing intervals.
2-3 hours for dihydroergotamine; 12-15 hours for ergoloid mesylates, requiring cautious dosing in hepatic impairment.
Primarily fecal (biliary) as metabolites and unchanged drug; renal elimination accounts for less than 10% of the dose.
Primarily hepatic metabolism (70-80%) with biliary excretion; renal excretion accounts for less than 10% of unchanged drug.
Category A/B
Category C
Ergot Alkaloid
Ergot Alkaloid